SUBSCRIBE
SUBSCRIBE
BioForest

FDA Cites GlaxoSmithKline for “Misleading” Letters

November 27, 2007 | 
1 min read

WASHINGTON - Government regulators have criticized GlaxoSmithKline for downplaying the risks of its breast cancer drug Tykerb, while exaggerating the benefits in letters to doctors.

GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: 3D rendering of antibody-drug conjugate/
BioForest
ADC-Focused ProfoundBio Raises $112M in Oversubscribed Series B
February 14, 2024
 · 
2 min read
 · 
Tyler Patchen
A moving truck parked in San Francisco’s Nob Hill
BioForest
How the Pandemic Shifted the Rules of Recruiting
October 25, 2023
 · 
4 min read
 · 
Amanda Heidt
2023 Hotbed Maps
Bio NC
BioSpace Releases Exclusive Hotbed Maps
January 5, 2023
 · 
4 min read
 · 
Lisa Munger